Kura Oncology (NASDAQ:KURA) Given Buy Rating at TD Cowen

TD Cowen reissued their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research report report published on Thursday morning,Benzinga reports.

Other analysts have also recently issued research reports about the stock. HC Wainwright raised their target price on shares of Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday. UBS Group started coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective for the company. JMP Securities reiterated a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research report on Tuesday, November 19th. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Finally, Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and decreased their price target for the company from $26.00 to $19.00 in a research note on Monday, October 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $29.38.

Kura Oncology Price Performance

Shares of NASDAQ KURA opened at $10.80 on Thursday. The stock has a market cap of $839.81 million, a P/E ratio of -4.58 and a beta of 0.86. The stock has a 50 day moving average of $17.88 and a two-hundred day moving average of $19.67. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a twelve month low of $9.06 and a twelve month high of $24.17.

Institutional Trading of Kura Oncology

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC raised its stake in shares of Kura Oncology by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock worth $34,798,000 after buying an additional 41,535 shares during the last quarter. Barclays PLC increased its holdings in Kura Oncology by 104.5% during the 3rd quarter. Barclays PLC now owns 165,484 shares of the company’s stock valued at $3,234,000 after acquiring an additional 84,563 shares in the last quarter. Jane Street Group LLC raised its position in Kura Oncology by 36.7% during the third quarter. Jane Street Group LLC now owns 126,085 shares of the company’s stock worth $2,464,000 after acquiring an additional 33,848 shares during the last quarter. Point72 DIFC Ltd acquired a new position in Kura Oncology during the third quarter worth about $146,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Kura Oncology in the third quarter valued at about $3,695,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.